Pharmacological therapeutics in Friedreich ataxia: the present state
Authors:
- 26 July 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 17 (9) , 895-907
Abstract
Introduction: Friedreich ataxia (FRDA) is a progressive, inherited, neurodegenerative disease for which there is currently no cure or approved treatment. FRDA is caused by deficits in the production and expression of frataxin, a protein found in the mitochondria that is most likely responsible for regulating iron-sulfur cluster enzymes within the cell. A decrease in frataxin causes dysfunction of adenosine triphosphate synthesis, accumulation of mitochondrial iron, and other events leading to downstream cellular dysfunction. Areas covered: Therapeutic development for FRDA currently focuses on improving mitochondrial function and finding ways to increase frataxin expression. Additionally, the authors will review potential approaches aimed at iron modulation and genetic modulation. Finally, gene therapy is progressing rapidly and is being explored as a treatment for FRDA. Expert commentary: The collection of multiple therapeutic approaches provides many possible ways to treat FRDA. Although the mitochondrial approaches are not thought to be curative, as the primary frataxin deficit will remain, they may still produce improvements in quality of life and slowing of progression. Therapies aimed at frataxin restoration are more likely to truly modify the disease, with gene therapy as the best possibility to alter the course of the disease from both a cardiac and neurological perspective.Keywords
Funding Information
- Freidreich Ataxia Research Alliance (none)
This publication has 111 references indexed in Scilit:
- Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia modelHuman Molecular Genetics, 2012
- A TAT–Frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse modelHuman Molecular Genetics, 2011
- PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's DiseaseCell, 2011
- Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial designMovement Disorders, 2010
- Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich’s ataxiaHuman Molecular Genetics, 2009
- Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyteProceedings of the National Academy of Sciences, 2009
- Impaired Nuclear Nrf2 Translocation Undermines the Oxidative Stress Response in Friedreich AtaxiaPLOS ONE, 2009
- HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse ModelPLOS ONE, 2008
- Antioxidant use in Friedreich ataxiaJournal of the Neurological Sciences, 2008
- Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxiaThe Cerebellum, 2006